| Negative regulation of humoral immunity due to interplay between the SLAMF1, SLAMF5, and SLAMF6 receptors N Wang, PJ Halibozek, B Yigit, H Zhao, MS O’Keeffe, P Sage, A Sharpe, ... Frontiers in immunology 6, 158, 2015 | 47 | 2015 |
| Increased β-cell proliferation before immune cell invasion prevents progression of type 1 diabetes E Dirice, S Kahraman, DF De Jesus, A El Ouaamari, G Basile, RL Baker, ... Nature metabolism 1 (5), 509-518, 2019 | 43 | 2019 |
| Migration of myeloid cells during inflammation is differentially regulated by the cell surface receptors Slamf1 and Slamf8 G Wang, BJ van Driel, G Liao, MS O’Keeffe, PJ Halibozek, J Flipse, B Yigit, ... PLoS One 10 (3), e0121968, 2015 | 42 | 2015 |
| SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer B Yigit, N Wang, E Ten Hacken, SS Chen, AK Bhan, A Suarez-Fueyo, ... Cancer immunology research 7 (9), 1485-1496, 2019 | 41 | 2019 |
| SAP-dependent and-independent regulation of innate T cell development involving SLAMF receptors J De Calisto, N Wang, G Wang, B Yigit, P Engel, C Terhorst Frontiers in immunology 5, 86926, 2014 | 41 | 2014 |
| Slamf6 negatively regulates autoimmunity N Wang, M Keszei, P Halibozek, B Yigit, P Engel, C Terhorst Clinical immunology 173, 19-26, 2016 | 31 | 2016 |
| A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells B Yigit, PJ Halibozek, SS Chen, MS O'Keeffe, J Arnason, D Avigan, ... Oncotarget 7 (18), 26346, 2016 | 20 | 2016 |
| SLAMF6 in health and disease: Implications for therapeutic targeting B Yigit, N Wang, RW Herzog, C Terhorst Clinical Immunology 204, 3-13, 2019 | 13 | 2019 |
| Inhibition of reactive oxygen species limits expansion of chronic lymphocytic leukemia cells B Yigit, N Wang, SS Chen, N Chiorazzi, C Terhorst Leukemia 31 (10), 2273-2276, 2017 | 10 | 2017 |
| SAP modulates B cell functions in a genetic background-dependent manner C Detre, B Yigit, M Keszei, W Castro, EM Magelky, C Terhorst Immunology letters 153 (1-2), 15-21, 2013 | 9 | 2013 |
| The checkpoint regulator SLAMF3 preferentially prevents expansion of auto-reactive B cells generated by graft-vs.-host disease N Wang, B Yigit, CE van der Poel, M Cuenca, MC Carroll, RW Herzog, ... Frontiers in Immunology 10, 425725, 2019 | 5 | 2019 |
| Persistence and tissue distribution of Agent-797–a native allogeneic iNKT ell-based cell therapy drug product MA Purbhoo, B Yigit, D Moskowitz, A Alsaraby, M Kirby, A Swarna, ... J Immuno Ther Cancer 9 (suppl 2), A432, 2021 | 3 | 2021 |
| Phase 1/2 Study of Agent-797, an Allogeneic Invariant Natural Killer T (Inkt) Cell Therapy, in Subjects with Moderate to Severe Acute Respiratory Distress Syndrome (Ards … M Purbhoo, B Yigit, X Michelet, R Smith, D Moskowitz, M Kirby, A Buffa, ... Journal for ImmunoTherapy of Cancer, A679-A679, 2022 | 2 | 2022 |
| Development of an allogeneic FAP-CAR iNKT product to target tumor stroma and modulate the tumor microenvironment X Michelet, M Popis, S Boi, R Masakayan, M Niedzielska, EA Sharoni, ... Presented at The Society for Immunotherapy of Cancer (SITC), 2022 | 1 | 2022 |
| agenT-797, a native allogeneic “off-the-shelf” invariant natural killer T (iNKT) cell therapy product improves effector functions within the tumor microenvironment S Pokharel, J Chamberland, YC Qin, D Moskowitz, R Masakayan, ... Presented at The Society for Immunotherapy of Cancer (SITC), 2022 | 1 | 2022 |
| Mink-413: A Next Generation Armored Allogenic Bcma Car Inkt Product E Chantzoura, EA Sharoni, R Masakayan, M Popis, D Moskowitz, P Ibbett, ... Journal for ImmunoTherapy of Cancer, A338-A338, 2022 | 1 | 2022 |
| Fc-enhanced anti-CTLA-4 antibody, AGEN1181: new mechanistic insights for potent antitumor immunity and combination potential in treatment-resistant solid tumors AJ Tanne, C Galand, A Abou-Slaybi, M Wilkens, M Marques, S Ng, H Han, ... Cancer Research 81 (13_Supplement), 1878-1878, 2021 | 1 | 2021 |
| A phase 1/2 clinical trial of invariant natural killer T cell therapy in moderate-severe acute respiratory distress syndrome TC Hammond, MA Purbhoo, S Kadel, J Ritz, S Nikiforow, H Daley, ... Nature Communications 15 (1), 974, 2024 | | 2024 |
| Safe Administration of Novel Allogeneic iNKT Cell Infusion to Four Patients With Severe COVID-19 Respiratory Failure (CARDS) Receiving Venovenous Extracorporeal Membrane … TC Hammond, MA Purbhoo, B Yigit, D Moskowitz, X Michelet, R Smith, ... A46. ECMO, ARDS, AND ACUTE RESPIRATORY FAILURE, A1718-A1718, 2023 | | 2023 |
| 647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma D Stevens, R Sanborn | | 2022 |
